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AbsTrACT
Objectives in 2016, WhO estimated 376 million 
new cases of the four main curable sTis: gonorrhoea, 
chlamydia, trichomoniasis and syphilis. Further, an 
estimated 290 million women are infected with human 
papillomavirus. sTis may lead to severe reproductive 
health sequelae. low- income and middle- income 
countries carry the highest global burden of sTis. a 
large proportion of urogenital and the vast majority 
of extragenital non- viral sTi cases are asymptomatic. 
screening key populations and early and accurate 
diagnosis are important to provide correct treatment and 
to control the spread of sTis. This article paints a picture 
of the state of technology of sTi point- of- care testing 
(POcT) and its implications for health system integration.
Methods The material for the sTi POcT landscape was 
gathered from publicly available information, published 
and unpublished reports and prospectuses, and 
interviews with developers and manufacturers.
results The development of sTi POcT is moving 
rapidly, and there are much more tests in the pipeline 
than in 2014, when the first sTi POcT landscape analysis 
was published on the website of WhO. several of the 
available tests need to be evaluated independently 
both in the laboratory and, of particular importance, in 
different points of care.
Conclusion This article reiterates the importance of 
accurate, rapid and affordable POcT to reach universal 
health coverage. While highlighting the rapid technical 
advances in this area, we argue that insufficient 
attention is being paid to health systems capacity and 
conditions to ensure the swift and rapid integration of 
current and future sTi POcT. Unless the complexity of 
health systems, including context, institutions, adoption 
systems and problem perception, are recognised and 
mapped, simplistic approaches to policy design and 
programme implementation will result in poor realisation 
of intended outcomes and impact.
InTrOduCTIOn
In 2016, WHO estimated 376 million new cases 
per year of the four main curable STIs: gonorrhoea 
(Neisseria gonorrhoeae (NG)), chlamydia (Chla-
mydia trachomatis (CT)), trichomoniasis (Tricho-
monas vaginalis (TV)) and syphilis (Treponema 
pallidum subspecies pallidum (TP)).1 In addition 
to CT, NG, TV and TP, Mycoplasma genitalium 
(MG) infections are prevalent in many settings.2 
An estimated 290 million women are infected with 
human papillomavirus (HPV),3 and an estimated 
3.9 million people live with HIV.4 Low- and middle- 
income countries (LMICs) carry the highest global 
burden of non- viral and viral STIs.5 6 STIs may lead 
to severe reproductive sequelae and neonatal death, 
are associated with the development of cancers 
resulting in high mortality, and can facilitate the 
transmission and acquisition of HIV.7
A large proportion of urogenital and the vast 
majority of extragenital non- viral STI cases are 
asymptomatic. These cases are most often identified 
through sexual contact notification, and particu-
larly opportunistic testing and screening. Screening 
or significantly enhanced testing of key popula-
tions and early and accurate diagnosis of infection 
are important to provide correct treatment and 
to control the spread of STIs and their sequelae.7 
Recent publications have called for the advance-
ment of point- of- care testing (POCT) for STIs, as 
they promise significantly improved performance 
compared with syndromic management. POCT 
potentially avoids overuse and misuse of antimi-
crobials and could thus decrease the selection of 
antimicrobial resistance (AMR) in STI pathogens 
and bystander commensal or pathogenic bacterial 
species, lower testing costs for patients and health-
care systems, reduce waiting times, speed up and 
increase accurate treatment, and improve patient 
follow- up.8–11 Accurate, rapid and affordable POCT 
could increase access to testing and identification 
of STIs in a single- patient visit in both LMICs and 
high- income countries (HICs) and could be used 
at all levels of the healthcare system while also 
contributing to the improvement of STI surveil-
lance through POCT connectivity.12
Diagnostics are often undervalued, but they are 
just as important to the attainment of the United 
Nations Sustainable Development Goals (SDGs) 
as medicines and vaccines. In particular, improved 
access to diagnostics will be essential to reach SDG 
3.7: ‘ensure universal access to sexual and repro-
ductive health care services, including for family 
planning, information and education, and the inte-
gration of reproductive health into national strate-
gies and programs’ and SDG 3.8: ‘achieve universal 
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Figure 1 Roadmap to advance point- of- care testing for the control 
and prevention of STIs (adapted from Toskin et al10).
Figure 2 Landscape for HIV/syphilis POCTs. TP, Treponema pallidum subspecies pallidum.
health coverage (UHC), including financial risk protection, 
access to quality essential health care services and access to safe, 
effective, quality and affordable essential medicines and vaccines 
for all’.13 In close alignment with the SDGs are WHO's triple 
billion goals, which include improved access to diagnostics for 
primary healthcare as a means to enable UHC for one billion 
more individuals.14 To achieve this goal, moving testing closer to 
the patient will be essential. WHO's Global health sector strategy 
for the Control and Prevention of STIs recognises STI POCT as 
an innovation that enables improvement in all steps of the STI 
services cascade (online supplementary appendix 1).7
To move the agenda forward, WHO has (1) facilitated several 
STI POCT landscape analyses, the first in 2014, and stakeholder 
meetings15 16; (2) developed target product profiles (TPPs); (3) 
established a global network of centres for and implemented 
studies to evaluate commercially available STI POC tests 
(POCTs); (4) developed a standard methodology for evaluation 
of STI POCTs and (5) developed a roadmap to accelerate the STI 
POCT agenda (figure 1).
Inspired by the global roadmap for STI vaccine development, 
the WHO International Advisory Group on STI POCT visually 
structured the roadmap along four main development phases 
necessary for advancing products from the concept stage to 
routine use: basic research, translation, evaluation and program-
matic implementation. Rather than linear, this is a cyclical 
roadmap, each element being informed by previous experi-
ences. Notwithstanding their potential to strengthen healthcare 
systems,17 the introduction of STI POCTs, allowing for more 
decentralisation, is not without risks. Currently, evidence from 
implementation studies and guidance and recommendations to 
sustain an effective introduction of such tools in primary care 
settings, particularly in LMICs, are lacking.
In the following sections, the present article summarises the 
STI POCT landscape, followed by a discussion of key health 
systems issues to be considered, as well as opportunities to 
strengthen health systems and improve health outcomes.
sTI POCT lAndsCAPe In 2018/2019
Over the past years, there have been an increasing number of 
POCTs for STIs developed, most of which are still in the pipe-
line, with expected launch in 2019 and beyond (figures 2 and 3).
HIV/syphilis
Simple, rapid, sensitive and specific POCTs for syphilis and HIV 
are already commercially available.18 However, some perfor-
mance anomalies suggest the need for additional evaluation 
studies. Optimisation of the available HIV/syphilis dual tests is 
still required to be in line with the WHO TPPs for use in primary 
healthcare settings in LMICs, as there are issues with multiple 
and complicated steps, timing, the inflexibility of the reading 
window, shelf life, environmental tolerances and, finally, cost.9 
There is only one novel assay in the pipeline, the mChip from 
Junco Labs (New York, New York, USA) and Columbia Univer-
sity in collaboration with OPKO Health (Miami, Florida, USA), 
which has been evaluated in Rwanda with good results,19 but no 
commercial launch date has been set.
nG/CT/TV/MG
Simple, rapid and equipment- free POCTs for the detection of 
CT, NG and TV are available but have a suboptimal sensitivity 
for screening or widely implemented testing.20–23 Nevertheless, 
emerging technologies promise major advances in the coming 
years.
Molecular tests for CT, NG and TV are now available from 
Molbio Diagnostics (Goa, India) for its Truelab Real Time micro 
PCR System and Cepheid (Sunnyvale, California, USA) for its 
GeneXpert system, both near- patient. A combined CT/NG test 
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Figure 3 Landscape for NG, CT, TV and HPV point- of- care testing. CT, Chlamydia trachomatis; HPV, human papillomavirus; NG, Neisseria 
gonorrhoeae; TV, Trichomonas vaginalis; MSTI, multi- STI; CPA, cross priming amplification; .
from Binx Health (formerly Atlas Genetics) (Trowbridge, UK) 
for its molecular io platform was also recently launched; a CT/
NG/TV/MG test is in the pipeline. A test for CT/NG is currently 
in the pipeline for the ID NOW platform (Abbott Laboratories, 
Lake Bluff, Illinois, USA), an instrument- based, molecular diag-
nostic test using isothermal nucleic acid amplification technology 
for the qualitative detection of CT/NG targets. Lucira Health 
(formerly Diassess) (Emeryville, California, USA) has an assay 
for CT/NG in the pipeline that is an instrument- free, deploy-
able, disposable and simple- to- use molecular test with a usability 
profile equivalent to current rapid immunoassay diagnostic tests. 
Further, QuantuMDx (Newcastle upon Tyne, UK) is planning 
to develop a CT/NG/TV/MG multiplex assay run direct from 
swab samples on a small, handheld diagnostic device, Q- POC, 
that can deliver patient results in under 15 min. The system runs 
end- point PCR chemistries and quantitative PCR chemistries, 
and includes a microarray after the amplification step. Randox 
(Crumlin, UK) has developed an STI array assay for the Bosch 
Vivalytic (Waiblingen, Germany) molecular platform, which uses 
microfluidic techniques to detect 10 bacterial, viral and proto-
zoan ‘STIs’, providing a comprehensive infection profile from 
a single urethral/vaginal swab and/or swab from ulcer samples, 
for example, Haemophilus ducreyi, TP, and herpes simplex virus 
type 1 (HSV-1) and 2 (HSV-2). The test panel for STIs includes 
CT, NG, TV and MG, as well as additional bacterial species 
Mycoplasma hominis and Ureaplasma urealyticum, which are 
frequently only colonising commensal bacteria that are not 
recommended to be routinely tested and treated as STIs.24
Blusense ViroTrack (Copenhagen, Denmark), which currently 
offers an assay for dengue virus, is planning to add certain STIs 
to its platform. It uses microfluidics and next- generation latex 
immune- turbidometry in the form of a patented optomagnetic 
nanoparticle- based readout technology which can be used to 
detect antigens, antibodies, small molecules, RNA, DNA and 
micro- RNA.
Antimicrobial resistance
AMR to all therapeutic antimicrobials in NG and MG has 
emerged, which compromises the treatment of these infections 
globally.2 25 26 In response, WHO has revitalised the WHO Global 
Gonococcal Antimicrobial Surveillance Programme.25 However, 
in many countries, cultured gonococcal isolates are becoming 
increasingly rare because of use of syndromic management or 
non- culture- based diagnostic methods.27 Accordingly, sensitive 
and specific tests that detect NG and MG AMR determinants to 
predict AMR for use particularly, but not exclusively, in primary 
and secondary healthcare settings would be exceedingly valu-
able. Rapid, accurate POCTs simultaneously detecting infection 
and predicting AMR could significantly impact treatment preci-
sion and infection management. This strategy would enable diag-
nosis and individualised treatment at the first healthcare visit, 
reducing selection pressure on currently recommended antimi-
crobials, reducing transmission of resistant NG and MG strains, 
and providing means for AMR surveillance.11 28 29 A modelling 
study in the UK showed that if a 30 min AMR POCT for NG 
and penicillin resistance would be available, 79% of the 33 431 
annual ceftriaxone treatments could possibly be replaced by 
benzylpenicillin.11 If a similar test with ciprofloxacin resistance 
were available, 66% of current treatment in the UK could be 
replaced by ciprofloxacin, both with considerable cost savings.
A number of prototypic POC devices for molecular detection, 
primarily targeting ciprofloxacin resistance or susceptibility in 
NG, are in the pipeline, but none is approved for routine use. 
However, developing appropriate AMR POCTs for most other 
therapeutic antimicrobials for NG, such as ceftriaxone and azith-
romycin, remain challenging.29 Furthermore, keys for successful 
deployment of these AMR POCTs will include understanding 
the cost consequences, cost- effectiveness and acceptability for 
key stakeholders.
A molecular POCT detecting ciprofloxacin susceptibility in 
NG is under development by Binx Health in cooperation with 
the St George’s Hospital, London, and QuantuMDx is devel-
oping an AMR NG POCT to complement its CT/NG/TV/MG 
multiplex assay. WHO supports the development and validation 
of NG AMR POCTs, and TPPs for these types of POCTs are 
currently under development.
Human papillomavirus
Molecular tests suitable for near- patient testing for HPV are 
already available from Cepheid, Qiagen (Hilden, Germany) 
and Molbio Diagnostics. New HPV assays are expected in the 
near future from GENOMICA (Madrid, Spain) for its NEDxA 
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Figure 4 Social construction perspective on health policy and systems (adapted from Sheikh et al).[w3].
platform and from Cepheid for its portable Omni platform. 
Furthermore, a partnership has been set up between Oncgnostics 
(Jena, Germany) and BLINK (Jena, Germany). Oncgnostics will 
develop its GynTect HPV assay for use on the BLINK platform. 
The system is anticipated to be both multiplexed and multiana-
lyte and designed for use at POC.
Several of the available tests need to be evaluated inde-
pendently both in the laboratory, and of particular importance, 
in different POC. It is clear that the development of STI POCTs 
is moving rapidly, but there is a gap when considering the readi-
ness of health systems to support the integration at several levels. 
These gaps range from identifying opportunities at global level 
for strategic procurement through global funding initiatives, 
normative technical implementation guidance and integration of 
such tests into national health systems.
sTI POCT HeAlTH sysTeMs InTeGrATIOn
Although aimed at the individual, health innovations such as 
POCT are implemented within health systems and often have 
implications that are more complex than first appreciated.30 
This recognition builds on the WHO definition of the health 
system as ‘consisting of all organisations, people and action 
whose primary intent is to promote, restore or maintain health’.
[w1] This notion of the health system requires moving beyond 
consideration of linear approaches comprising static health 
system building blocks (ie, service delivery, health workforce, 
health information, medical technologies, health financing, lead-
ership and governance) to recognising the complex web of inter- 
relationships and pathways of influence that transform these 
blocks into people- centred systems.30 This requires taking an 
aerial view of the whole system when considering the implemen-
tation of innovations.[w2]
As illustrated in figure 4, health systems comprise both 'hard-
ware' and 'software'; moreover, rather than being a vehicle for 
technological innovations, they are grounded in political and 
social contexts, on international and national as well as subna-
tional and local levels, with underlying power structures, inter-
ests and interdependencies.[w3]
Top- down, simplistic approaches to the introduction of inno-
vations such as POCT, which only focus on the implications for 
the hardware components of the system (eg, training of health 
workers to apply a new technology or improvements in supply- 
chain management) and ignore the software and system- wide 
elements, including cultural norms and historical trajectories, 
run the risk of unexpected and, in some instances, adverse 
outcomes. This implies and demands a health systems research 
agenda encompassing:
1. Normative/evaluation or exploratory/explanatory questions 
driven by social science research methods in addition to clin-
ical and epidemiological research employing both qualitative 
and quantitative methodological tools.
2. Inquiry at multiple levels of analysis, including mapping the 
context, institutions and adoption systems. This requires 
‘macro- level focuses on the architecture of systems, meso- 
level on the functioning of organizations and systemic inter-
ventions, and micro level on the role of individuals involved 
in activities of health provision, utilization, and governance, 
and how systems respectively shape and are shaped by their 
decisions and behaviour’.[w3]
This health system research agenda should not be undertaken 
in isolation. Much knowledge and lessons have been learnt 
from the introduction of POCT into national health systems 
for other STIs, such as HIV. Ongoing global initiatives for the 
dual elimination of mother- to- child transmission (MTCT) of 
HIV and syphilis and the triple elimination of MTCT of HIV, 
syphilis and hepatitis B are examples of how countries can 
leverage the efforts and resources that have been invested in 
HIV programmes to improve prenatal screening for syphilis, 
an STI that is often forgotten.[w4] STIs and POCT feature 
prominently in the Global HIV/STI and Viral Hepatitis Strategy 
and the 2018 Astana Declaration on primary healthcare. SDG 
3.8.1., ‘Coverage of essential health services’ and the Global 
Health Sector Strategy on STIs provide further opportunities for 
building STI POCT into global and national initiatives. For HPV, 
the director- general of WHO has made a global call for action 
towards the elimination of cervical cancer. Together with HPV 
vaccination, screening programmes will be essential to achieve 
this goal. POCT for HPV should be clearly positioned as the tool 
par excellence for screening, both in HICs and LMICs, as well 
as for routine monitoring of HPV prevalence.[w5] POCT is also 
indispensable in the battle against AMR. WHO's Global Action 
Plan calls on the research community to invest in the develop-
ment of effective and low- cost POCTs for detection of AMR.
[w6]
The publication of the WHO Essential Diagnostics List (EDL) 
in 2018 and 2019 highlighted the importance of diagnostics 
that can be used at lower levels of the healthcare system and 
will likely influence regional and national policy.[w7,w8] While 
the current EDL includes mainly laboratory based diagnostics 
for STIs (HIV, syphilis, NG and CT) and only POCTs for HIV 
and syphilis, there is a need for advocating for more STI POCTs 
in forthcoming editions, accompanied by a set of easy- to- use 
guidelines for developing STI POCT policy and programme 
implementation.
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Equally important is securing funding to support policy and 
programme implementation within LMICs. Sustainable funding 
dedicated to STI POCTs is direly needed. However, as Kuupiel 
et al (2017) observed,[w9] even if sufficient investment is made 
in securing the availability of POCT in general, there are health 
system barriers that challenge their adoption in LMICs. These 
include a combination of hardware and software challenges at the 
national, subnational and local levels, including financial, human 
resources, policy regulatory, infrastructure, quality control and 
quality assurance, work–flow balance, training of personnel, 
supply chain, relationships between healthcare workers and 
patients and cultural acceptability of POCTs. It is important to 
re- emphasise that a well- functioning POCT programme should 
be informed by findings of the research agenda as described 
previously, but countries should also consider investing in data 
connectivity so that test results from thousands of POCT sites 
around a country are not just being recorded on registers and 
only reported or analysed periodically. Digitising laboratory and 
POC test results can standardise the interpretation of results 
and allows data to be linked to proficiency testing to ensure 
testing quality, reducing interpretation and transcription errors. 
Weak health systems in LMICs contribute to almost a quarter 
of healthcare equipment being out of service.[w10] Remote 
monitoring of POC instrument functionality and use through 
connectivity allows programmes to optimise instrument place-
ment, algorithm adoption and supply management. Alerts can 
be built into the system to raise alarm at unusual trends such as 
outbreaks. Connected diagnostics have become a useful tool for 
epidemiology, patient care and tracking, research, and AMR and 
outbreak surveillance.[w11]17
When introducing health innovations such as STI POCT, 
context- appropriate communication is important. As Atun et al 
(2012) argue ‘…the reasons for slow adoption and diffusion of 
health innovations are less to do with the perceived benefits of 
the innovation, but the way the problem, which the innovation 
is designed to address, is perceived by the individuals and the 
adoption system within health institutions, the health system and 
the broad context’.[w2] If stakeholder perception of the problem 
and the innovation to address the problem are disparate with the 
evidence of the benefits of the innovation, then poor adoption 
and, in some instances, resistance may ensue. For example, in 
Russia, the incorrect perception that HIV/AIDS was a problem 
associated mainly with injecting drug users and sex workers 
resulted in poor uptake of antiretroviral therapy.[w12] The 
introduction of POCT for syphilis has been shown to strengthen 
health systems by increasing access to prenatal care for a greater 
percentage of the population, increasing system efficiency by 
reducing the number of patient visits and improving patient 
outcomes.[w13,w14]
It is also important to recognise the role of key stakeholders 
in getting buy- in and ensuring the successful diffusion of innova-
tions. For example, in relation to scaling up innovations in Ethi-
opia, Spicer et al note: “…if an innovation is a new technology, 
vaccine or medication and/or requires changes in national legisla-
tion they first approach federal government, whereas expanding 
programs accepted by federal government required targeting 
relevant Regional Health Bureaus”.[w15]
Hence stakeholder engagement and buy- in and effective 
communication should reflect that investment in the proper 
introduction and scale- up of STI POCT is an investment in 
health system strengthening in LMICs.
COnClusIOn
For STI POCT to support WHO's goal of ending STI epidemics 
as public health concerns by 2030, it must be recognised that 
health systems barriers challenge the successful adoption and 
implementation of STI POCT.[w16] A health systems research 
agenda integrating effective and existing STI POCT technologies 
into health systems can and should be taken forward immediately 
through a combination of demonstration and implementation 
research projects. This is essential for building a body of knowl-
edge that recognises the complexity of developing a responsive 
and effective health system for addressing the transmission and 
burden of STIs through POCT.
References from w1 to w16 are available in online supplemen-
tary appendix 2.
Key messages
 ► Accurate, rapid and affordable point- of- care testing (POCT) 
for sexually transmitted infections are important tools to 
reach the goal of the WHO STI Global health sector strategy, 
ending STI epidemics as major public health concerns.
 ► The development of STI POCTs is moving rapidly; although 
they will not all make it to the finish line, there have never 
been more POCTs in the pipeline to detect gonorrhoea, 
chlamydia, trichomoniasis and the human papillomavirus.
 ► The roll- out of STI POCT is not sufficiently prepared: there are 
no opportunities at a global level for strategic procurement; 
normative technical implementation guidance for integration 
of STI POCT into national health systems is urgently needed.
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